Primary biliary cirrhosis: what we know and what we want to know about human PBC and spontaneous PBC mouse models

被引:22
|
作者
Ueno, Yoshiyuki
Moritoki, Yuki
Shimosegawa, Tooru
Gershwin, M. Eric
机构
[1] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Univ Calif Davis, Sch Med, Div Clin Immunol & Rheumatol, Davis, CA 95616 USA
关键词
autoimmunity; cholestatic liver disease; animal model; heterogeneity; cholangiocyte; NORMAL RAT-LIVER; INTRAHEPATIC BILE-DUCTS; PDC-E2; 163-176; PEPTIDE; NECROSIS-FACTOR-ALPHA; T-CELL RESPONSES; EPITHELIAL-CELLS; MOLECULAR MIMICRY; MITOCHONDRIAL AUTOANTIGENS; INTRAEPITHELIAL LYMPHOCYTES; INCREASED EXPRESSION;
D O I
10.1007/s00535-007-2019-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Human autoimmune cholangiopathy comprises several intractable liver diseases that ultimately lead to hepatic failure. Primary biliary cirrhosis (PBC), allograft rejection, graft versus host diseases, and, possibly, primary sclerosing cholangitis are representative of immune-mediated cholangiopathies. Among them, PBC is the best-investigated human autoimmune cholangiopathy. The immunological approach to PBC has provided much critical information regarding its pathogenesis. The breakdown of self-tolerance in both B cells and T cells toward E2 components of the pyruvate dehydrogenase complex is evident. However, a number of questions regarding its etiology are unclear, in particular, the mechanisms involved in the selectivity of cholangiocyte destruction. In this brief review, we discuss what we know and we do not know regarding the pathogenesis of PBC.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 50 条
  • [31] We know what we want, it's just not there
    Freundlich, Robert E.
    Lindsell, Christopher J.
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 6 (01)
  • [32] Autoimmune chronic spontaneous urticaria: What we know and what we do not know
    Kolkhir, Pavel
    Church, Martin K.
    Weller, Karsten
    Metz, Martin
    Schmetzer, Oliver
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (06) : 1772 - +
  • [33] WHAT WE KNOW ABOUT WHAT STUDENTS DONT KNOW
    ANRIG, GR
    LAPOINTE, AE
    EDUCATIONAL LEADERSHIP, 1989, 47 (03) : 4 - &
  • [34] What we know, what we don't know and what we need to know
    Chapple, Christopher R.
    MacNeil, Sheila
    CURRENT OPINION IN UROLOGY, 2019, 29 (04) : 378 - 379
  • [35] What we know and what we do not know
    McDonald, JC
    RADIATION PROTECTION DOSIMETRY, 2005, 113 (02) : 127 - 128
  • [36] Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon
    Swerdlow, NR
    Braff, DL
    Geyer, MA
    BEHAVIOURAL PHARMACOLOGY, 2000, 11 (3-4): : 185 - 204
  • [37] Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?
    Bielcikova, Zuzana
    Jakabova, Anna
    Pinkas, Michael
    Zemanova, Milada
    Kolostova, Katarina
    Bobek, Vladimir
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (06): : 2807 - 2823
  • [38] What We Know and What We Don't Know About Preventing Stroke
    Burch, Druin
    PLOS MEDICINE, 2014, 11 (04)
  • [39] What we know and what we need to know about developmental aluminum toxicity
    Golub, MS
    Domingo, JL
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH, 1996, 48 (06): : 585 - 597
  • [40] Using the BRAIN to LEARN: Utilizing What We Know About What We Know
    Boles, Jeremy
    CREATIVE APPROACHES TO TECHNOLOGY-ENHANCED LEARNING FOR THE WORKPLACE AND HIGHER EDUCATION, VOL 1, TLIC 2024, 2024, 1150 : 24 - 33